Pharma Business Daily
Claim your FREE trial subscription!


Cancer:

Allos Therapeutics Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing  September 2005

Paper - GBP 95.00  
Single-user PDF - GBP 95.00  


Table of Contents

Allos Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Allos Therapeutics was incorporated on 1st September 1992 as HemoTech Sciences and filed amended Articles of
Incorporation to change its name to Allos Therapeutics on 19th October 1994. The company reincorporated on 28th
October 1996.
Allos is a biopharmaceutical company focused on developing and commercialising innovative small-molecule drugs for
improving cancer treatments. Its lead compound is efaproxiral, a synthetic small molecule, which it believes can be
used to improve existing cancer treatments and treat many diseases and clinical conditions attributed to or aggravated
by oxygen deprivation.

Number of pages - 14
 




For full details, please email keithw@cmsinfo.com

Order Form



CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel:     +44 (0)1494 771734
Fax:   +44 (0)1494 778994
e-mail: Jennifer Cowlard
copyright © 2008 all rights reserved

For more information about us, visit CMSinfo.

footer bar